The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
EKSO BIONICS HLDGS INC | COM | 282644301 | 6,505 | 774,400 | SH | SOLE | 0 | 774,400 | 0 | ||
BELLEROPHON THERAPEUTICS INC | COM NEW | 078771300 | 14,481 | 1,153,846 | SH | SOLE | 0 | 1,153,846 | 0 | ||
CORVUS PHARMACEUTICALS INC | COM | 221015100 | 103 | 38,010 | SH | SOLE | 0 | 38,010 | 0 | ||
SCYNEXIS INC | COM | 811292101 | 2,336 | 3,111,436 | SH | SOLE | 0 | 3,111,436 | 0 |